China SXT Pharmaceuticals (SXTC) Non-Current Debt (2018 - 2026)

China SXT Pharmaceuticals has reported Non-Current Debt for 9 years, with the latest figure at $644390.0 in Q1 2026.

• On a quarterly basis, Non-Current Debt rose 569.4% year-over-year to $644390.0 in Q1 2026; TTM through Mar 2026 was $644390.0, a 569.4% increase from a year earlier, with the FY2026 full-year figure at $644390.0, up 569.4% from the prior year.
• Non-Current Debt was $644390.0 for Q1 2026 at China SXT Pharmaceuticals, up from $73102.0 in the prior quarter.
• The five-year high for Non-Current Debt was $1.1 million in Q1 2022, with the low at $73102.0 in Q3 2025.
• Average Non-Current Debt over 5 years is $299140.5, with a median of $116236.5 recorded in 2024.
• The sharpest annual moves came in 2022 and 2023: Non-Current Debt soared 17739.45% in 2022, then plunged 89.5% in 2023.
• Over 5 years, Non-Current Debt stood at $1.1 million in 2022, then plunged by 90.51% to $106575.0 in 2023, then rose by 8.23% to $115344.0 in 2024, then tumbled by 36.62% to $73102.0 in 2025, then jumped by 781.49% to $644390.0 in 2026.
• The last three Non-Current Debt figures came in at $644390.0 (Q1 2026), $73102.0 (Q3 2025), and $96264.0 (Q1 2025), per Business Quant data.